OpenAI Rejects Apple Trade Secret Theft Claims 
France Targets Shein, Temu With Fast-Fashion Fees 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Bessent Urges Japan on Fiscal Discipline, BOJ Rate Hikes 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Oil Prices Rise as US-Iran Conflict Threatens Middle East Supply 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Australia Current Account Deficit Widens to A$27.2 Billion 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
FTSE 100 Falls as US-Iran Conflict Drives Oil Prices Higher 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
Samsung Biologics and AstraZeneca are reportedly dissolving their biosimilar joint venture. They have formed the Archigen Biotech for the JV, and now this is being shut down.
An official of Samsung Biologics, the biotech unit of the Samsung Group, said on Tuesday, May 24, that it has decided to end its joint venture with the British-Swedish multinational pharmaceutical and biotechnology company due to the suspension of the development of a biosimilar product.
According to Yonhap News Agency, the decision came two months after the Samsung Biologics’ board agreed with the liquidation of Archigen Biotech Ltd. The said company was set up in 2014 via a 50-50 joint venture with AstraZeneca.
When it was first established, Archigen Biotech was working on the development of SAIT101, a biosimilar of Rituximab, a monoclonal antibody medication used for the treatment of lymphoma. It was explained that a biosimilar is a similar duplication of an already existing and approved biologic drug.
However, both Samsung Biologics and AstraZeneca halted the biosimilar program and scrapped the Rituxan copy project. It was revealed to have been actually discontinued in the second half of 2020 after competitors such as Celltrion Inc. started marketing the same products.
Fierce Pharma further reported that Archigen Biotech already launched a phase 3 trial of the SAIT101 in June 2016, but the works have been progressing very slowly. In fact, the original target date for the completion of the project has already been pushed back by more than a year.
The results of the trial were revealed last month and showed that the Rituxan biosimilar medication generated a response in 66.3% of patients, which is on par with the 70.6% posted by the originator.
But then, another issue has cropped up - the market for this product is already crowded with other biotech firms introducing their own biosimilars, with some already being sold. Aside from Celltrion, Achigen Biotech is also competing with Teva Pharmaceuticals, Pfizer, Mylan, and Novartis’ Sandoz. With all of these firms, it became apparent to Samsung Biologics and AstraZeneca that the best move now is to scrap their own Rituxan biosimilar product.
